( BRIDGEWATER N.J.--(BUSINESS WIRE)--Apr...)Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting,Health

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Apr 12, 2007 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that four posters containing preclinical data will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held from April 14 - 18, 2007 in Los Angeles, CA.

Details of the presentations are as follows:

-- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38 conjugate, has potent antitumor activity in a panel of human tumor xenografts (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 8.)

-- Abstract #1496: EZN-2208, a novel poly ethylene glycol-SN38 conjugate, improves pharmacological properties of SN38 in mice and rats. (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 10.)

-- Abstract #4731: Customized positive PEG linkers for the delivery of antisense molecules (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 14.)

-- Abstract #4726: In vitro and in vivo evaluation of PEGylated anti-Bcl2 siRNA conjugates in a Bcl-2 over-expressing lung cancer model (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 9.)

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two o
'"/>

Page: 1 2
Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference